Search

Despite advances in biotechnology and research, the lack of specialists, scarcity of treatments, and inequality in access to medical services remain crucial challenges for patients and their families.

The possibilities are certainly immense, but they require sustained R&D efforts and an environment that facilitates such developments.

According to the INE report, if we exclusively analyze the figure for companies, we observe that R&D investment increased by 5% compared to 2021. In 2022, the figure stood at 1.223 billion euros

BLUEREMEDIOMICS is expected to facilitate increased aquaculture production under more efficient food production and reduced environmental footprint scenarios.

The increasing complexity of clinical trials and evolving regulatory requirements pose significant challenges for Sponsors, CROs and Research Entities.

The initiative is coming to an end after three years of activity (2022-2024), accompanying the growth of eleven entities in the healthcare sector.

Miramoon Pharma has hit a major milestone with the publication of preclinical data for its two lead candidates in top-tier peer-reviewed journals.

The SEBBM, in collaboration with the Carmen and Severo Ochoa Foundation, launch the Severo Ochoa Conferences, which will deal monographically with research topics on the frontier of knowledge and will

BCN HEALTH has published 10 studies in 2024 that assess the incidence, productivity loss, and cost of disease for different diseases in Spain.

Meet Biointaxis, our new member. We spoke with Antoni Matilla Dueñas CEO, Co-fundador.

Integra Therapeutics has developed the FiCAT gene-writing platform to develop cell therapies for autoimmune and oncology diseases and gene therapies for rare diseases. The company recently announced a

To contribute to the democratization of access to new cell therapies, Klinea works on various initiatives. The project explained below is an example of this commitment.

We trust that this decision will help reduce the bottleneck caused by the high demand for certification under the new regulatory framework and the limited availability of certification capacities

En la Fase de madurez del ciclo de vida de un proyecto es necesario idear estrategias de crecimiento para evitar el declive

Repsol, through its investment arm Repsol Corporate Venturing, has acquired a 21.43% stake in DARWIN Bioprospecting Excellence, a Valencian startup that is a leader in biotechnology, focusing on